Jan Serroyen
Overview
Explore the profile of Jan Serroyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Fits L, de Jong R, Dijkman K, Heemskerk-van der Meer M, Tettero L, Bonsing J, et al.
NPJ Vaccines
. 2024 Nov;
9(1):235.
PMID: 39587114
Vaccination with Ad26.RSV.preF, an Adenoviral serotype 26 vector encoding RSV F protein stabilized in its prefusion conformation, has previously shown to be immunogenic and protective in RSV seropositive adults and...
2.
Vijayan A, Vogels R, Groppo R, Jin Y, Khan S, Van Kampen M, et al.
Nat Commun
. 2024 Nov;
15(1):9884.
PMID: 39543172
Newly approved subunit and mRNA vaccines for respiratory syncytial virus (RSV) demonstrate effectiveness in preventing severe disease, with protection exceeding 80% primarily through the generation of antibodies. An alternative vaccine...
3.
Marquez-Martinez S, Khan S, Lubbe J, Solforosi L, Costes L, Choi Y, et al.
Vaccines (Basel)
. 2024 May;
12(5).
PMID: 38793810
Ad26.COV2.S vaccination can lead to vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but severe adverse effect, characterized by thrombocytopenia and thrombosis. The mechanism of VITT induction is unclear and likely...
4.
Marquez-Martinez S, Salisch N, Serroyen J, Zahn R, Khan S
PLoS One
. 2024 Apr;
19(4):e0299215.
PMID: 38626093
Non-replicating adenovirus-based vectors have been broadly used for the development of prophylactic vaccines in humans and are licensed for COVID-19 and Ebola virus disease prevention. Adenovirus-based vectored vaccines encode for...
5.
Khan S, Marquez-Martinez S, Erkens T, de Wilde A, Costes L, Vinken P, et al.
Vaccines (Basel)
. 2023 Dec;
11(12).
PMID: 38140195
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a very rare but serious adverse reaction that can occur after Ad26.COV2.S vaccination in humans, leading to thrombosis at unusual anatomic sites. One hypothesis...
6.
McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann N, et al.
Nature
. 2023 Dec;
626(7998):385-391.
PMID: 38096903
A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with current Omicron subvariants, although they still provide protection against severe disease. Enhanced mucosal immunity may...
7.
Saeland E, van der Fits L, Bolder R, Heemskerk-van der Meer M, Drijver J, van Polanen Y, et al.
NPJ Vaccines
. 2023 Mar;
8(1):45.
PMID: 36949051
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously shown that a prefusion (preF) conformation-stabilized RSV F...
8.
Khan S, Salisch N, Izquierdo Gil A, Boedhoe S, Feddes-de Boer K, Serroyen J, et al.
NPJ Vaccines
. 2022 Nov;
7(1):146.
PMID: 36379957
The adenovirus (Ad)26 serotype-based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity...
9.
Tiemessen M, Solforosi L, Dekking L, Czapska-Casey D, Serroyen J, Sullivan N, et al.
Vaccines (Basel)
. 2022 Aug;
10(8).
PMID: 36016151
The Marburg virus (MARV) and Sudan virus (SUDV) belong to the filovirus family. The sporadic human outbreaks occur mostly in Africa and are characterized by an aggressive disease course with...
10.
Saeland E, van der Fits L, Bolder R, Heemskerk-van der Meer M, Drijver J, van Polanen Y, et al.
Vaccine
. 2022 Jan;
40(6):934-944.
PMID: 34973849
Respiratory Syncytial Virus (RSV) remains a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously described the derivation of an RSV Fusion protein...